Abstract
Hepatocarcinogenesis is a multistep process developing from a normal liver through chronic hepatitis and cirrhosis to HCC. The pathogenesis of HCC is poorly understood at present. There is insufficient understanding to propose a robust general model of hepatic carcinogenesis, partly because the pathogenic host and environmental factors show significant regional variation, making such generalization difficult. However, with advances in molecular technology, there is a growing understanding of the molecular mechanisms in the development of HCC. In hepatocarcinogenesis, there is a strong link to increases in allelic losses, chromosomal changes, gene mutations, epigenetic alterations and alterations in molecular cellular pathways. In this chapter, special focus is placed on the multistep process of hepatocarcinogenesis, genetics, epigenetics and regulation of major signaling pathways involved in hepatocarcinogenesis. A detailed understanding of the molecular pathogenesis involved in the progression of HCC can improve our prevention and diagnostic tools for HCC and may help identify novel molecular targets for new therapies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Roncalli M. Hepatocellular nodules in cirrhosis: focus on diagnostic criteria on liver biopsy. A Western experience. Liver Transpl, 2004, 10: S9–S15.
Ferrell L D, Crawford J M, Dhillon A P, et al. Proposal for standardized criteria for the diagnosis of benign, borderline, and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol, 1993, 17: 1113–1123.
Kobayashi M, Ikeda K, Hosaka T, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer, 2006, 106: 636–647.
Mion F, Grozel L, Boillot O, et al. Adult cirrhotic liver explants: precancerous lesions and undetected small hepatocellular carcinomas. Gastroenterology, 1996, 111: 1587–1592.
Lee J M, Wong C M, Ng I O. Hepatitis B virus-associated multistep hepatocarcinogenesis: a stepwise increase in allelic alterations. Cancer Res, 2008, 68: 5988–5996.
Thursz M R, Kwiatkowski D, Allsopp C E, et al. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med, 1995, 332: 1065–1069.
Hohler T, Gerken G, Notghi A, et al. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol, 1997, 26: 503–507.
Ahn S H, Han K H, Park J Y, et al. Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology, 2000, 31: 1371–1373.
Bellamy R, Ruwende C, Corrah T, et al. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis, 1999, 179: 721–724.
Deng G, Zhou G, Zhai Y, et al. Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection. Hepatology, 2004, 40: 318–326.
King J K, Yeh S H, Lin M W, et al. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. Hepatology, 2002, 36: 1416–1424.
Yu M W, Chang H C, Liaw Y F, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst, 2000, 92: 1159–1164.
Yu M W, Chang H C, Chen P J, et al. Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol, 2002, 31: 1008–1015.
Kummee P, Tangkijvanich P, Poovorawan Y, et al. Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat, 2007, 14: 841–848.
Gu X, Qi P, Zhou F, et al. +49G>A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol, 2010, 71: 83–87.
Patil M A, Gutgemann I, Zhang J, et al. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis, 2005, 26: 2050–2057.
Yoon Y J, Chang H Y, Ahn S H, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis, 2008, 29:1192–1196.
Migita K, Miyazoe S, Maeda Y, et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection: association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol, 2005, 42: 505–510.
Tseng C S, Tang K S, Lo H W, et al. UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age. Am J Gastroenterol, 2005, 100: 1758–1763.
Shih W L, Yu M W, Chen P J, et al. Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area. Oncogene, 2006, 25: 3219–3124.
Xu T, Zhu Y, Wei Q K, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis, 2008, 29: 2126–2131.
Nagasue N, Yamanoi A, Takemoto Y, et al. Comparison between diploid and aneuploid hepatocellular carcinomas: a flow cytometric study. Br J Surg, 1992, 79: 667–670.
Attallah A M, Tabll A A, Salem S F, et al. DNA ploidy of liver biopsies from patients with liver cirrhosis and hepatocellular carcinoma: a flow cytometric analysis. Cancer Lett, 1999, 142: 65–69.
Kawai H, Suda T, Aoyagi Y, et al. Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: comparison of loss of heterozygosity and replication error. Hepatology, 2000, 31: 1246–1250.
Kuroki T, Fujiwara Y, Tsuchiya E, et al. Accumulation of genetic changes during development and progression of hepatocellular carcinoma: loss of heterozygosity of chromosome arm 1p occurs at an early stage of hepatocarcinogenesis. Genes Chromosomes Cancer, 1995, 13: 163–167.
Li S P, Wang H Y, Li J Q, et al. Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. J Hepatol, 2001, 34: 840–849.
Nagai H, Pineau P, Tiollais P, et al. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene, 1997, 14: 2927–2933.
Okabe H, Ikai I, Matsuo K, et al. Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and-negative tumors. Hepatology, 2000, 31: 1073–1079.
Piao Z, Park C, Park J H, et al. Allelotype analysis of hepatocellular carcinoma. Int J Cancer, 1998, 75: 29–33.
Bando K, Nagai H, Matsumoto S, et al. Identification of a 1-cM region of common deletion on 4q35 associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer, 1999, 25: 284–289.
Bluteau O, Beaudoin J C, Pasturaud P, et al. Specific association between alcohol intake, high grade of differentiation and 4q34–q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. Oncogene, 2002, 21: 1225–1232.
Chan K L, Lee J M, Guan X Y, et al. High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation. Cancer, 2002, 94: 3179–3185.
Emi M, Fujiwara Y, Ohata H, et al. Allelic loss at chromosome band 8p21.3–p22 is associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer, 1993, 7: 152–157.
Piao Z, Park C, Park J H, et al. Deletion mapping of chromosome 4q in hepatocellular carcinoma. Int J Cancer, 1998, 79: 356–360.
Pineau P, Nagai H, Prigent S, et al. Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma. Oncogene, 1999, 18: 3127–3134.
Wong C M, Lee J M, Lau T C, et al. Clinicopathological significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma. Clin Cancer Res, 2002, 8: 2266–2272.
Tamura S, Nakamori S, Kuroki T, et al. Association of cumulative allelic losses with tumor aggressiveness in hepatocellular carcinoma. J Hepatol, 1997, 27: 669–676.
Raidl M, Pirker C, Schulte-Hermann R, et al. Multiple chromosomal abnormalities in human liver (pre)neoplasia. J Hepatol, 2004, 40: 660–668.
Kahng Y S, Lee Y S, Kim B K, et al. Loss of heterozygosity of chromosome 8p and 11p in the dysplastic nodule and hepatocellular carcinoma. J Gastroenterol Hepatol, 2003, 18: 430–436.
Sun M, Eshleman J R, Ferrell L D, et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36–p34 region. Hepatology, 2001, 33: 1415–1424.
Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology, 2001, 120: 1763–1773.
Kallioniemi A, Kallioniemi O P, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science, 1992, 258: 818–821.
Marchio A, Meddeb M, Pineau P, et al. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer, 1997, 18: 59–65.
Zondervan P E, Wink J, Alers J C, et al. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J Pathol, 2000, 192: 207–215.
Wong N, Lai P, Lee S W, et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol, 1999, 154: 37–43.
Tornillo L, Carafa V, Richter J, et al. Marked genetic similarities between hepatitis B virus-positive and hepatitis C virus-positive hepatocellular carcinomas. J Pathol, 2000, 192: 307–312.
Kusano N, Shiraishi K, Kubo K, et al. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology, 1999, 29: 1858–1862.
Guan X Y, Fang Y, Sham J S, et al. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer, 2000, 29: 110–116.
Collonge-Rame M A, Bresson-Hadni S, Koch S, et al. Pattern of chromosomal imbalances in non-B virus related hepatocellular carcinoma detected by comparative genomic hybridization. Cancer Genet Cytogenet, 2001, 127: 49–52.
Kusano N, Okita K, Shirahashi H, et al. Chromosomal imbalances detected by comparative genomic hybridization are associated with outcome of patients with hepatocellular carcinoma. Cancer, 2002, 94: 746–751.
Sakakura C, Hagiwara A, Taniguchi H, et al. Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparative genomic hybridization. Br J Cancer, 1999, 80: 2034–2039.
Fang W, Piao Z, Simon D, et al. Mapping of a minimal deleted region in human hepatocellular carcinoma to 1p36.13–p36.23 and mutational analysis of the RIZ (PRDM2) gene localized to the region. Genes Chromosomes Cancer, 2000, 28: 269–275.
Russell S E, McIlhatton M A, Burrows J F, et al. Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors. Cancer Res, 2000, 60: 4729–4734.
Albertson D G, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet, 2000, 25: 144–146.
Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet, 1998, 20: 207–211.
Ching Y P, Wong C M, Chan S F, et al. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem, 2003, 278: 10824–10830.
Wong C C, Wong C M, Ko F C, et al. Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS One, 2008, 3: e2779.
Leung T H, Ching Y P, Yam J W, et al. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci USA, 2005, 102: 15207–15212.
Wong C M, Yam J W, Ching Y P, et al. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res, 2005, 65: 8861–8868.
Zhou X, Thorgeirsson S S, Popescu N C. Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene, 2004, 23: 1308–1313.
Cheng I K, Ching A K, Chan T C, et al. Reduced CRYL1 expression in hepatocellular carcinoma confers cell growth advantages and correlates with adverse patient prognosis. J Pathol, 2009, 220: 348–360.
Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature, 1999, 398: 160–165.
Ruddon R W (ed). Cancer Biology. 3rd edn. New York: Oxford University Press, 1995.
Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet, 1991, 338: 1356–1359.
Scorsone K A, Zhou Y Z, Butel J S, et al. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res, 1992, 52: 1635–1638.
Ng I O, Chung L P, Tsang S W, et al. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene, 1994, 9: 985–990.
Ng I O, Lai E C, Chan A S, et al. Overexpression of p53 in hepatocellular carcinomas: a clinicopathological and prognostic correlation. J Gastroenterol Hepatol, 1995, 10: 250–255.
Hsu I C, Metcalf R A, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature, 1991, 350: 427–428.
Dumenco L, Oguey D, Wu J, et al. Introduction of a murine p53 mutation corresponding to human codon 249 into a murine hepatocyte cell line results in growth advantage, but not in transformation. Hepatology, 1995, 22: 1279–1288.
Ponchel F, Puisieux A, Tabone E, et al. Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res, 1994, 54: 2064–2068.
Eferl R, Ricci R, Kenner L, et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell, 2003, 112: 181–192.
Wong C M, Fan S T, Ng I O. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer, 2001, 92: 136–145.
Terris B, Pineau P, Bregeaud L, et al. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene, 1999, 18: 6583–6588.
de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA, 1998, 95: 8847–8851.
Hsu H C, Jeng Y M, Mao T L, et al. beta-Catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol, 2000, 157: 763–770.
Taniguchi K, Roberts L R, Aderca I N, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene, 2002, 21: 4863–4871.
Nhieu J T, Renard C A, Wei Y, et al. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol, 1999, 155: 703–710.
Cieply B, Zeng G, Proverbs-Singh T, et al. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology, 2009, 49: 821–831.
Nishida N, Nishimura T, Nagasaka T, et al. Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. Cancer Res, 2007, 67: 4586–4594.
Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet, 2003, 33 Suppl: 228–237.
Risch N J. Searching for genetic determinants in the new millennium. Nature, 2000, 405: 847–856.
Shin H D, Park B L, Kim L H, et al. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet, 2003, 12: 901–906.
Miyazoe S, Hamasaki K, Nakata K, et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol, 2002, 97: 2086–2092.
Zhai Y, Zhou G, Deng G, et al. Estrogen receptor alpha polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology, 2006, 130: 2001–2009.
Saffroy R, Pham P, Chiappini F, et al. The MTHFR 677C>T polymorphism is associated with an increased risk of hepatocellular carcinoma in patients with alcoholic cirrhosis. Carcinogenesis, 2004, 25: 1443–1448.
Yuan J M, Lu S C, Van Den Berg D, et al. Genetic polymorphisms in the methylenetetrahydrofolate reductase and thymidylate synthase genes and risk of hepatocellular carcinoma. Hepatology, 2007, 46: 749–758.
Wang X Q, Luk J M, Garcia-Barcelo M, et al. Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinoma. Clin Cancer Res, 2006, 12: 5248–5252.
Segat L, Milanese M, Pirulli D, et al. Secreted protein acidic and rich in cysteine (SPARC) gene polymorphism association with hepatocellular carcinoma in Italian patients. J Gastroenterol Hepatol, 2009, 24: 1840–1846.
Kim Y S, Cheong J Y, Cho S W, et al. A functional snp of the interleukin-18 gene is associated with the presence of hepatocellular carcinoma in hepatitis B virus-infected patients. Dig Dis Sci, 2009, 54: 2722–2728.
Ezzikouri S, El Feydi A E, Benazzouz M, et al. Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. Infect Genet Evol, 2009, 9: 877–881.
Wu Y, Lin J S. DNA methyltransferase 3B promoter polymorphism and its susceptibility to primary hepatocellular carcinoma in the Chinese Han nationality population: a case-control study. World J Gastroenterol, 2007, 13: 6082–6086.
Hunter D J, Kraft P, Jacobs K B, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet, 2007, 39: 870–874.
Easton D F, Pooley K A, Dunning A M, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447: 1087–1093.
Li E, Bestor T H, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell, 1992, 69: 915–926.
Wong N, Lam W C, Lai P B, et al. Hypomethylation of chromosome 1 heterochromatin DNA correlates with q-arm copy gain in human hepatocellular carcinoma. Am J Pathol, 2001, 159: 465–471.
Saito Y, Kanai Y, Sakamoto M, et al. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology, 2001, 33: 561–568.
Nambu S, Inoue K, Saski H. Site-specific hypomethylation of the c-myc oncogene in human hepatocellular carcinoma. Jpn J Cancer Res, 1987, 78: 695–704.
Lin C H, Hsieh S Y, Sheen I S, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res, 2001, 61: 4238–4243.
Antequera F, Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci USA, 1993, 90: 11995–11999.
Panning B, Jaenisch R. RNA and the epigenetic regulation of X chromosome inactivation. Cell, 1998, 93: 305–308.
Greger V, Passarge E, Hopping W, et al. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet, 1989, 83: 155–158.
Kanai Y, Ushijima S, Hui A M, et al. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int J Cancer, 1997, 71: 355–359.
Kaneto H, Sasaki S, Yamamoto H, et al. Detection of hypermethylation of the p16 (INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut, 2001, 48: 372–377.
Oh B K, Kim H, Park H J, et al. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int J Mol Med, 2007, 20: 65–73.
Lee S, Lee H J, Kim J H, et al. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol, 2003, 163: 1371–1378.
Schagdarsurengin U, Wilkens L, Steinemann D, et al. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene, 2003, 22: 1866–1871.
Zhong S, Tang M W, Yeo W, et al. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res, 2002, 8: 1087–1092.
Yoshikawa H, Matsubara K, Qian G S, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet, 2001, 28: 29–35.
Shih Y L, Shyu R Y, Hsieh C B, et al. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer, 2006, 107: 579–590.
Wong C M, Lee J M, Ching Y P, et al. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res, 2003, 63: 7646–7651.
Wang L, Wang W L, Zhang Y, et al. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res, 2007, 37: 389–396.
Wong I H, Lo Y M, Zhang J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res, 1999, 59: 71–73.
Zhang Y J, Wu H C, Shen J, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res, 2007, 13: 2378–2384.
Lee R C, Feinbaum R L, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75: 843–854.
Alvarez-Garcia I, Miska E A. MicroRNA functions in animal development and human disease. Development, 2005, 132: 4653–4662.
Slack F J, Basson M, Liu Z, et al. The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. Mol Cell, 2000, 5: 659–669.
Calin G A, Dumitru C D, Shimizu M, et al. Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA, 2002, 99: 15524–15529.
Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res, 2007, 67: 6092–6099.
Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 2007, 133: 647–658.
Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of micro RNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene, 2006, 25: 2537–2545.
Budhu A, Jia H L, Forgues M, et al. Identification of metastasis-related micro RNAs in hepatocellular carcinoma. Hepatology, 2008, 47: 897–907.
Jiang J, Gusev Y, Aderca I, et al. Association of micro RNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res, 2008, 14: 419–427.
Wang Y, Kato N, Jazag A, et al. Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response. Gastroenterology, 2006, 130: 883–892.
Melo S A, Ropero S, Moutinho C, et al. A TARBP2 mutation in human cancer impairs micro RNA processing and DICER1 function. Nat Genet, 2009, 41: 365–370.
He L, Thomson J M, Hemann M T, et al. A micro RNA polycistron as a potential human oncogene. Nature, 2005, 435: 828–833.
Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 2008, 27: 5651–5661.
Pineau P, Volinia S, McJunkin K, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA, 2010, 107: 264–269.
Coulouarn C, Factor V M, Andersen J B, et al. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene, 2009, 28: 3526–3536.
Lin C J, Gong H Y, Tseng H C, et al. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun, 2008, 375: 315–320.
Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med, 2009, 361: 1437–1447.
Kota J, Chivukula R R, O’Donnell K A, et al. Therapeutic micro RNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009, 137: 1005–1017.
Chen X, Cheung S T, So S, et al. Gene expression patterns in human liver cancers. Mol Biol Cell, 2002, 13: 1929–1939.
Delpuech O, Trabut J B, Carnot F, et al. Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma. Oncogene, 2002, 21: 2926–2937.
Goldenberg D, Ayesh S, Schneider T, et al. Analysis of differentially expressed genes in hepatocellular carcinoma using cDNA arrays. Mol Carcinog, 2002, 33: 113–124.
Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res, 2001, 61: 2129–2137.
Shirota Y, Kaneko S, Honda M, et al. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology, 2001, 33: 832–840.
Xu L, Hui L, Wang S, et al. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res, 2001, 61: 3176–3181.
Xu X R, Huang J, Xu Z G, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA, 2001, 98: 15089–15094.
Iizuka N, Oka M, Yamada-Okabe H, et al. Comparison of gene expression profiles between hepatitis B virus-and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res, 2002, 62: 3939–3944.
Westermarck J, Kahari V M. Regulation of matrix metalloproteinase expression in tumor invasion. Faseb J, 1999, 13: 781–792.
Maatta M, Soini Y, Liakka A, et al. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res, 2000, 6: 2726–2734.
Clark E A, Golub T R, Lander E S, et al. Genomic analysis of metastasis reveals an essential role for RhoC. Nature, 2000, 406: 532–535.
Hakem A, Sanchez-Sweatman O, You-Ten A, et al. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev, 2005, 19: 1974–1979.
Wang W, Yang L Y, Huang G W, et al. Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer, 2004, 90: 2349–2355.
Wang W, Yang L Y, Yang Z L, et al. Expression and significance of RhoC gene in hepatocellular carcinoma. World J Gastroenterol, 2003, 9: 1950–1953.
Huang J, Sheng H H, Shen T, et al. Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virus-associated hepatocellular carcinoma. FEBS Lett, 2006, 580: 3571–3581.
Lee S A, Ho C, Roy R, et al. Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology, 2008, 47: 1200–1210.
El-Serag H B, Rudolph K L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132: 2557–2576.
Villanueva A, Newell P, Chiang D Y, et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis, 2007, 27: 55–76.
Huelsken J, Behrens J. The Wnt signalling pathway. J Cell Sci, 2002, 115: 3977–3978.
Clevers H. Wnt/beta-catenin signaling in development and disease. Cell, 2006, 127: 469–480.
Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol, 2007, 19: 150–158.
He T C, Sparks A B, Rago C, et al. Identification of c-myc as a target of the APC pathway. Science, 1998, 281: 1509–1512.
Tetsu O, McCormick F. beta-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature, 1999, 398: 422–426.
Huang H, Fujii H, Sankila A, et al. beta-Catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol, 1999, 155: 1795–1801.
Cui J, Zhou X, Liu Y, et al. Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes. J Gastroenterol Hepatol, 2003, 18: 280–287.
Cottrell S, Bicknell D, Kaklamanis L, et al. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet, 1992, 340: 626–630.
Yang B, Guo M, Herman J G, et al. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol, 2003, 163: 1101–1107.
Colnot S, Decaens T, Niwa-Kawakita M, et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci USA, 2004, 101: 17216–17221.
Ryo A, Nakamura M, Wulf G, et al. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol, 2001, 3: 793–801.
Pang R, Yuen J, Yuen M F, et al. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene, 2004, 23: 4182–4186.
Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet, 2000, 24: 245–250.
Chan D W, Chan C Y, Yam J W, et al. Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/ degradation in liver cancer. Gastroenterology, 2006, 131: 1218–1227.
Uematsu K, He B, You L, et al. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene, 2003, 22: 7218–7221.
Uematsu K, Kanazawa S, You L, et al. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res, 2003, 63: 4547–4551.
Yau T O, Chan C Y, Chan K L, et al. HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing. Oncogene, 2005, 24: 1607–1614.
Bengochea A, de Souza M M, Lefrancois L, et al. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer, 2008, 99: 143–150.
Kim M, Lee H C, Tsedensodnom O, et al. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol, 2008, 48: 780–791.
Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci, 2003, 116: 2627–2634.
Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet, 2002, 31: 141–149.
Takagi H, Sasaki S, Suzuki H, et al. Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol, 2008, 43: 378–389.
Mao B, Wu W, Li Y, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature, 2001, 411: 321–325.
Qin X, Zhang H, Zhou X, et al. Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells. Transl Res, 2007, 150: 281–294.
Merle P, de la Monte S, Kim M, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology, 2004, 127: 1110–1122.
Merle P, Kim M, Herrmann M, et al. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol, 2005, 43: 854–862.
Tolwinski N S, Wehrli M, Rives A, et al. Wg/Wnt signal can be transmitted through arrow/LRP5,6 and Axin independently of Zw3/Gsk3beta activity. Dev Cell, 2003, 4: 407–418.
Tamai K, Semenov M, Kato Y, et al. LDL-receptor-related proteins in Wnt signal transduction. Nature, 2000, 407: 530–535.
Satoh T, Kaziro Y. Ras in signal transduction. Semin Cancer Biol, 1992, 3: 169–177.
Vojtek A B, Der C J. Increasing complexity of the Ras signaling pathway. J Biol Chem, 1998, 273: 19925–19928.
Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev, 1998, 8: 49–54.
Avruch J, Zhang X F, Kyriakis J M. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci, 1994, 19: 279–283.
Ogata N, Kamimura T, Asakura H. Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma. Hepatology, 1991, 13: 31–37.
Weihrauch M, Benicke M, Lehnert G, et al. Frequent k-ras-2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer, 2001, 84: 982–989.
Nonomura A, Ohta G, Hayashi M, et al. Immunohistochemical detection of ras oncogene p21 product in liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol, 1987, 82: 512–518.
Wang Q, Lin Z Y, Feng X L. Alterations in metastatic properties of hepatocellular carcinoma cell following H-ras oncogene transfection. World J Gastroenterol, 2001, 7: 335–339.
Jacob J R, Tennant B C. Transformation of immortalized woodchuck hepatic cell lines with the c-Ha-ras proto-oncogene. Carcinogenesis, 1996, 17: 631–636.
Osada S, Kanematsu M, Imai H, et al. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg, 2005, 201: 405–411.
Schuierer M M, Bataille F, Weiss T S, et al. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep, 2006, 16: 451–456.
Lee H C, Tian B, Sedivy J M, et al. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology, 2006, 131: 1208–1217.
Yoshida T, Hisamoto T, Akiba J, et al. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene, 2006, 25: 6056–6066.
Vos M D, Ellis C A, Bell A, et al. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem, 2000, 275: 35669–35672.
Calvisi D F, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and JAK/STAT pathways in human HCC. Gastroenterology, 2006, 130: 1117–1128.
Zhong S, Yeo W, Tang M W, et al. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Clin Cancer Res, 2003, 9: 3376–3382.
Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science, 2004, 304: 554.
Tanaka Y, Kanai F, Tada M, et al. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene, 2006, 25: 2950–2952.
Lee J W, Soung Y H, Kim S Y, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene, 2005, 24: 1477–1480.
Hu T H, Huang C C, Lin P R, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer, 2003, 97: 1929–1940.
Fujiwara Y, Hoon D S, Yamada T, et al. PTEN/MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas. Jpn J Cancer Res, 2000, 91: 287–292.
Bhaskar P T, Hay N. The two TORCs and Akt. Dev Cell, 2007, 12: 487–502.
Blanco-Aparicio C, Renner O, Leal J F, et al. PTEN, more than the Akt pathway. Carcinogenesis, 2007, 28: 1379–1386.
Nakanishi K, Sakamoto M, Yamasaki S, et al. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer, 2005, 103: 307–312.
Xu X, Sakon M, Nagano H, et al. Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol Rep, 2004, 11: 25–32.
Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell, 2005, 8: 179–183.
Sahin F, Kannangai R, Adegbola O, et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res, 2004, 10: 8421–8425.
Semela D, Piguet A C, Kolev M, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol, 2007, 46: 840–848.
Yuan B Z, Miller M J, Keck C L, et al. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res, 1998, 58: 2196–2199.
Ng I O, Liang Z D, Cao L, et al. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res, 2000, 60: 6581–6584.
Yam J W, Ko F C, Chan C Y, et al. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res, 2006, 66: 8367–8372.
Kim T Y, Lee J W, Kim H P, et al. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun, 2007, 355: 72–77.
Zhou X, Zimonjic D B, Park S W, et al. DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis. Int J Oncol, 2008, 32: 1285–1291.
Xue W, Krasnitz A, Lucito R, et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev, 2008, 22: 1439–1444.
Liao YC, Si L, deVere White RW, et al. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol, 2007, 176: 43–49.
Qian X, Li G, Asmussen H K, et al. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA, 2007, 104: 9012–9017.
Liao Y C, Shih Y P, Lo S H. Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function. Cancer Res, 2008, 68: 7718–7722.
Zheng S L, Mychaleckyj J C, Hawkins G A, et al. Evaluation of DLC1 as a prostate cancer susceptibility gene: mutation screen and association study. Mutat Res, 2003, 528: 45–53.
Durkin M E, Ullmannova V, Guan M, et al. Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth. Oncogene, 2007, 26: 4580–4589.
Kawai K, Kiyota M, Seike J, et al. START-GAP3/DLC3 is a GAP for RhoA and Cdc42 and is localized in focal adhesions regulating cell morphology. Biochem Biophys Res Commun, 2007, 364: 783–789.
Yam J W, Ko F C, Chan C Y, et al. Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma. Hepatology, 2006, 44: 881–890.
Lin K H, Shieh H Y, Chen S L, et al. Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog, 1999, 26: 53–61.
Yeh S H, Chiu C M, Chen C L, et al. Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma. Int J Cancer, 2007, 120: 1610–1617.
Soung Y H, Lee J W, Kim S Y, et al. Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas. Oncogene, 2005, 24: 141–147.
Kremer-Tal S, Reeves H L, Narla G, et al. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology, 2004, 40: 1047–1052.
Cho Y G, Kim C J, Song J H, et al. Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas. Exp Mol Med, 2006, 38: 247–255.
Kim C J, Cho Y G, Park J Y, et al. Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas. Eur J Cancer, 2004, 40: 136–141.
Xie H J, Bae H J, Noh J H, et al. Mutational analysis of JAK1 gene in human hepatocellular carcinoma. Neoplasma, 2009, 56: 136–140.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2012 Zhejiang University Press, Hangzhou and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wong, C., Ng, I.O.L. (2012). Genomics of Hepatocellular Carcinoma. In: Primary Liver Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-28702-2_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-28702-2_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-28701-5
Online ISBN: 978-3-642-28702-2
eBook Packages: MedicineMedicine (R0)